We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Maecenas is a fine art investment platform, allowing collectors to raise funds and investors to own a piece of fine art they would not normally be able to afford such as a picasso or even a Rembrandt! The investment made in the Artwork can easily be re-sold using the Maecenas platform and all investments are fully protected by insurance and a strong legal framework. 
days to go: Expired investment: £218,249
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly. 
days to go: Expired investment: £116,960
Beart are the first reward-based crowdfunding platform that is designed specifically for art. It's aim is to bring together artists, curators, galleries, collectors, museums and foundations. 
days to go: Expired investment: £78,151
Thymia aims to empower clinicians with cutting-edge Neuroscience and AI objectively identify and track mental illness using speech, facial movements and behaviour patterns, enabling personalised, efficient treatment and accurate remote monitoring. They have a large dataset, successful sales, and are raising funds for medical regulation, ADHD expansion, and patent filings. 
days to go: Expired investment: £1,126,464
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go: Expired investment: £451,506
PopUp Painting (PUP) is an art company that aims to be the leader in organising experiential social painting events in the UK. The company endeavours to bring art out of the classroom and gallery into the places people meet on an everyday basis, thereby, unleashing creativity. PUP has hosted over 45,000 guests to date. Total revenues to date are £1.1 million. In the last financial year, the company generated revenues of £373,000. The COVID-19 pandemic in March led to PUP launching its online art sessions which was met with positive feedback. The company resumed hosting in-person COVID-secure events from July 2020 onwards. PUP is seeking £175,000 at a pre-money valuation of £1.3 million to launch its own Central London experiential events space and to expand its current services to reach a new product market.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
GalleriesNow is a revolutionary art platform rapidly becoming the most trusted source of information on galleries, artists and exhibitions worldwide. We have achieved tremendous traction in the space of one year, already working with Frieze Art Fair, Soho House and the FT and in discussions with major arts publications - and are an increasingly valuable way for galleries to interact with their audiences. We are fundraising to consolidate and bring further revenue streams on-line. Our goal is to be the perfect bridge between gallery and art buyer - join us on our journey!
days to go: Expired investment: £33,384
Regenerative Medical Group provides a remedy for Wound Healing and Erectile Dysfunction (ED) by using non-invasive technology. It partners with clinics to render the service such as reception, treatment rooms and nurses. In addition to the Erectile Dysfunction (ED) market, it has identified wound healing as a new market. Currently, it is working with an experienced NHS/NICE validation team to show its value as a treatment modality. RMG reached revenues of £400k, -56k EBITDA in the financial year 2017, and is operational in 5 clinics.
days to go: Expired investment: £67,740
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph